Showing 4061-4070 of 5300 results for "".
- Study IDs Additional Risk Allele in Allopurinol-Induced Cutaneous Reactions in US Patientshttps://practicaldermatology.com/news/study-ids-additional-risk-allele-in-allopurinol-induced-cutaneous-reactions-in-us-patients/2484235/A recently published genetic association study has identified HLA-A34:02 as an independent allele significantly associated with severe cutaneous adverse reactions (SCARs) to allopurinol in a US-based cohort. Researchers from
- Combination of Clascoterone 1% and Adapalene 0.3% Shows Promise for Acnehttps://practicaldermatology.com/news/combination-of-clascoterone-1-and-adapalene-03-shows-promise-for-acne/2484118/Combination therapy with clascoterone cream 1% and adapalene gel 0.3% significantly improves acne severity and quality of life, while maintaining excellent tolerability in patients with moderate-to-severe acne vulgaris, according to a 16-week pilot study presented
- Skin Cancer Champions Launches Integrated Public, Private Communityhttps://practicaldermatology.com/news/skin-cancer-champions-launches-integrated-public-private-community/2484106/The Skin Cancer Champions organization, led by dermatologists Emily Ruiz, MD, MPH, and Chrysalyne Schmults, MD, MSce, FAAD, announced the official launch of its integrated public and private community at skincancerchampions.org. The public platform expands the group’s reach by offering edu
- Dr. Darrell Rigel Highlights Advances in Skin Cancer Carehttps://practicaldermatology.com/news/dr-darrell-rigel-highlights-advances-in-skin-cancer-care/2484095/Darrell S. Rigel, MD, MS, provided a comprehensive update on the rapidly evolving landscape of skin cancer diagnosis, treatment, and prognostication at the 2025 Fall Clinical Dermatology Conference. From novel genetic assays to refinements in field therapy and systemic strategies, Dr. Rigel’s tal
- CHE Talk at Fall Clinical Highlights Precision Therapieshttps://practicaldermatology.com/news/che-talk-at-fall-clinical-highlights-precision-therapies/2484094/With new FDA approvals, investigational therapies nearing the finish line, and a greater understanding of disease heterogeneity, chronic hand eczema (CHE) is increasingly viewed as a condition requiring individualized, mechanistically informed care, Alexandra Golant, MD, and Benjamin Ehst, MD, Ph
- Emerging Treatments for CLE Highlighted at Fall Clinicalhttps://practicaldermatology.com/news/emerging-treatments-for-cle-highlighted-at-fall-clinical/2484091/Cutaneous lupus erythematosus (CLE) patients often face long treatment timelines, drug toxicity, and misdiagnoses, but recent advances in mechanism-based agents mark a significant step forward, Lauren Graham, MD, PhD, and Alisa Femia, MD, said during a presentation at the 2025 Fall Clinical Derma
- Dr. Andrew Alexis Highlights 2-MNG as Option to Treat Acne-Related PIHhttps://practicaldermatology.com/news/dr-andrew-alexis-highlights-2-mng-as-option-to-treat-acne-related-pih/2483902/The topical agent 2-Mercaptonicotinoyl glycine (2-MNG), also marketed as Melasyl, could be key to treating acne-related postinflammatory hyperpigmentation (PIH) in skin of color, Andrew Alexis, MD, MPH, said at the Skin of Color Update in New York, New York. Dr. Alexis presented on managin
- Analysis: Ceramide Skincare from Birth May Mitigate Pediatric ADhttps://practicaldermatology.com/news/analysis-ceramide-skincare-from-birth-may-mitigate-pediatric-ad/2483872/A new consensus paper offers clinical recommendations to address the complex interplay of skin barrier dysfunction and SAIGE (Staphylococcus aureus colonization, immunologic, genetic, and environmental) factors in pediatric atopic dermatitis (AD).
- Biologics Most Likely to Be Continued After MACE: Studyhttps://practicaldermatology.com/news/biologics-most-likely-to-be-continued-after-mace-study/2483287/Biologic therapies were linked with greater treatment persistence than non-biologic systemic agents or phototherapy among patients with psoriasis who experience major adverse cardiovascular events (MACE), according to findings from a retrospective study of Korean n
- Study: Azelaic Acid Shows Positive Outcomes in Pregnant Acne Patientshttps://practicaldermatology.com/news/study-azelaic-acid-offers-superior-outcomes-in-pregnant-acne-patients/2483218/New retrospective data on topical therapies for acne vulgaris during pregnancy suggested azelaic acid demonstrated greater efficacy compared to erythromycin or clindamycin. The study, conducted between 2018 and 2022, analyzed